1. No category

Principal Investigator/Program Director (Last, first, middle): Principal Investigator/Program Director (Last, first, middle): .
BIOGRAPHICAL SKETCH
Provide the following information for the key personnel in the order listed for Form Page 2.
Follow the sample format for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
Muzikansky Alona
Bioinformatics specialist II
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
DEGREE
(if applicable)
INSTITUTION AND LOCATION
Hebrew University, Jerusalem, Israel
Hebrew University, Jerusalem, Israel
B.A.
M.A.
YEAR(s)
FIELD OF STUDY
1996 Statistics & Economics
1998 Statistics & Economics
A. Positions and Employment. Positions and Employment
1998­1998
1999­2002
2002­
Statistician and Economic Analyst, Agam Information System, Jerusalem, Isarel
Biostatistician, MGH Biostatistics Center, Boston, MA
Bioinformatics specialist, MGH Biostatistics Center, Boston, MA Other Experience 1996­ 1998
1996­ 1998
Teaching assistant, Hebrew University, Jerusalem, Israel
Credit Analyst, Tefahot Bank of Israel, Jerusalem, Israel
B. Selected peer­reviewed publications. 1. Campos SM. Penson RT. Mays AR. Berkowitz RS. Fuller AF. Goodman A. Matulonis UA. Muzikansky A. Seiden MV. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecologic Oncology. 81(2):206­12, 2001 May.
2. Shapiro GI. Supko JG. Patterson A. Lynch C. Lucca J. Zacarola PF. Muzikansky A. Wright JJ. Lynch TJ Jr. Rollins BJ. A phase II trial of the cyclin­dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non­small cell lung cancer. Clinical Cancer Research. 7(6):1590­9, 2001 Jun.
3. Chakravarti A. Delaney MA. Noll E. Black PM. Loeffler JS. Muzikansky A. Dyson NJ. Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clinical Cancer Research. 7(8):2387­95, 2001 Aug.
4. Pierie JP. Muzikansky A. Gaz RD. Faquin WC. Ott MJ. The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Annals of Surgical Oncology. 9(1):57­64, 2002 Jan­Feb.
5. Pierie JP. Choudry U. Muzikansky A. Finkelstein DM. Ott MJ. Prognosis and management of extramammary Paget's disease and the association with secondary malignancies.[see comment]. Journal of the American College of Surgeons. 196(1):45­50, 2003 Jan.
PHS 398/2590 (Rev. 5/01)
Page
Biographical Sketch Format Page
Principal Investigator/Program Director (Last, first, middle): 6. Dadras SS. Paul T. Bertoncini J. Brown LF. Muzikansky A. Jackson DG. Ellwanger U. Garbe C. Mihm MC. Detmar M. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. American Journal of Pathology. 162(6):1951­60, 2003 Jun.
7. Finkelstein DM. Muzikansky A. Schoenfeld DA. Comparing survival of a sample to that of a standard population. Journal of the National Cancer Institute. 95(19):1434­9, 2003 Oct 1.
8. Nestler U. Wakimoto H. Siller­Lopez F. Aguilar LK. Chakravarti A. Muzikansky A. Stemmer­
Rachamimov A. Chiocca EA. Aguilar­Cordova E. Hochberg FH. The combination of adenoviral HSV TK gene therapy and radiation is effective in athymic mouse glioblastoma xenografts without increasing toxic side effects. Journal of Neuro­Oncology. 67(1­2):177­88, 2004 Mar­Apr.
9. Chakravarti A. Zhai G. Suzuki Y. Sarkesh S. Black PM. Muzikansky A. Loeffler JS. The prognostic significance of phosphatidylinositol 3­kinase pathway activation in human gliomas. Journal of Clinical Oncology. 22(10):1926­33, 2004 May 15.
10. Deshpande V. Fernandez­del Castillo C. Muzikansky A. Deshpande A. Zukerberg L. Warshaw AL. Lauwers GY. Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors. American Journal of Surgical Pathology. 28(9):1145­53, 2004 Sep.
11. Gupta V. Carey JL. Kawakubo H. Muzikansky A. Green JE. Donahoe PK. MacLaughlin DT. Maheswaran S. Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model. Proceedings of the National Academy of Sciences of the United States of America. 102(9):3219­24, 2005 Mar 1.
12. Livestro DP, Muzikansky A, Kaine EM, Flotte TJ, Sober AJ, Mihm MC Jr, Michaelson JS, Cosimi AB, Tanabe KK. Biology of desmoplastic melanoma: a case­control comparison with other melanomas. J Clin Oncol. 2005 Sep 20;23(27):6739­46.
13. Wang SA, Wang L, Hochberg EP, Muzikansky A, Harris NL, Hasserjian RP. Low Histologic Grade Follicular Lymphoma With High Proliferation Index: Morphologic and Clinical Features. Am J Surg Pathol. 2005 Nov;29(11):1490­1496.
14. Zhu AX, Fuchs CS, Clark JW, Muzikansky A, Taylor K, Sheehan S, Tam K, Yung E, Kulke MH, Ryan DP. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist. 2005 Jun­Jul;10(6):392­8.
15. Rosand J, Muzikansky A, Kumar A, Wisco JJ, Smith EE, Betensky RA, Greenberg SM. Spatial clustering of hemorrhages in probable cerebral amyloid angiopathy. Ann Neurol. 2005 Sep;58(3):459­62.
16. Dadras SS, Lange­Asschenfeldt B, Velasco P, Nguyen L, Vora A, Muzikansky A, Jahnke K, Hauschild A, Hirakawa S, Mihm MC, Detmar M. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol. 2005 Sep;18(9):1232­42.
17. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006 Jan 20;24(3):401­6
18. Bellovin DI, Bates RC, Muzikansky A, Rimm DL, Mercurio AM,. Altered localization of p120 catenin during epithelial to mesenchymal transition of colon carcinoma is prognostic for aggressive disease. Cancer Res. 2005 Dec 1;65(23):10938­45.
19. Andrew X. Zhu, Lawrence S. Blaszkowsky, David P. Ryan, Jeffrey W. Clark, Alona Muzikansky, Kerry Horgan, Susan Sheehan, Kelly E. Hale, Peter C. Enzinger, Pankaj Bhargava, Keith Stuart,. Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology, Vol 24, No 12 (April 20), 2006: pp. 1898­1903.
20. Kulke MH, Muzikansky A, Clark J, Enzinger PC, Fidias P, Kinsella K, Michelini A, Fuchs CS,. A Phase II Trial of Vinorelbine in Patients with Advanced Gastroesophageal Adenocarcinoma. Cancer Invest. 2006 Jun­Jul;24(4):346­50.
PHS 398/2590 (Rev. 5/01)
Page
Biographical Sketch Format Page
Principal Investigator/Program Director (Last, first, middle): 21. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez­delCastillo C, Warshaw AL,. Perioperative CA19­9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006 Jun 20;24(18):2897­902.
22. Kawakubo H, Brachtel E, Hayashida T, Yeo G, Kish J, Muzikansky A, Walden PD, Maheswaran S,. Loss of B­cell translocation gene­2 in estrogen receptor­positive breast carcinoma is associated with tumor grade and overexpression of cyclin d1 protein. Cancer Res. 2006 Jul 15;66(14):7075­82.
23. Del Carmen MG, Findley M, Muzikansky A, Roche M, Verrill CL, Horowitz N, Seiden MV. Demographic, risk factor, and knowledge differences between Latinas and non­Latinas referred to colposcopy. Gynecol Oncol. 2006 Aug 29; [Epub ahead of print].
24. Lam P, Berman S, Thurer R, Ashiku S, DeCamp M, Goldstein M, Schumer S, Halmos B, Karp D, Coute D, Bergman M, Boyd­Sirard C, Ou SH, Muzikansky A, Woodard C, Huberman M. Phase II trial of sequential chemotherapy followed by chemoradiation, surgery, and postoperative chemotherapy for the treatment of stage IIIA/IIIB non­small­cell lung cancer. Clin Lung Cancer. 2006 Sep;8(2):122­9.
25. Shannon KM, Muzikansky A, Chan­Smutko G, Niendorf KB, Ryan PD. Uptake of BRCA1 rearrangement panel testing: in individuals previously tested for BRCA1/2 mutations. Genet Med. 2006 Dec;8(12):740­5.
26. Sequist LV, Joshi VA, Janne PA, Muzikansky A, Fidias P, Meyerson M, Haber DA, Kucherlapati R, Johnson BE, Lynch TJ. Response to treatment and survival of patients with non­small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist. 2007 Jan;12(1):90­8.
27. Soupir CP, Vergilio JA, Cin PD, Muzikansky A, Kantarjian H, Jones D, Hasserjian RP. Philadelphia chromosome­positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol. 2007 Apr;127(4):642­50.
28. R P Hasserjian , H J B Goodman , H J Lachmann , A Muzikansky , P N Hawkins. Bone marrow findings correlate with clinical outcome in systemic AL amyloidosis patients. Histopathology. 2007 Apr ;50 (5):567­73.
29. Santosh Kesari , David Schiff , Lisa Doherty , Debra C Gigas , Tracy T Batchelor , Alona Muzikansky , Alison O'neill , Jan Drappatz , Alice S Chen­Plotkin , Naren Ramakrishna , Stephanie E Weiss , Brenda Levy , Joanna Bradshaw , Jean Kracher , Andrea Laforme , Peter McL Black , Judah Folkman , Mark Kieran , Patrick Y Wen. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro­oncol. 2007 Apr 23.
30. Temel JS, Jackson VA, Billings JA, Dahlin C, Block SD, Buss MK, Ostler P, Fidias P, Muzikansky A, Greer JA, Pirl WF, Lynch TJ. Phase II study: integrated palliative care in newly diagnosed advanced non­small­cell lung cancer patients. J Clin Oncol. 2007 Jun 10;25(17):2377­82.
31. Blacker D, Lee H, Muzikansky A, Martin EC, Tanzi R, McArdle JJ, Moss M, Albert M. Neuropsychological measures in normal individuals that predict subsequent cognitive decline. Arch Neurol. 2007 Jun;64(6):862­71.
32. Livestro DP, Kaine EM, Michaelson JS, Mihm MC, Haluska FG, Muzikansky A, Sober AJ, Tanabe KK. Melanoma in the young: differences and similarities with adult melanoma: a case­matched controlled analysis. Cancer. 2007 Aug 1;110(3):614­24.
33. Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, Enzinger PC, Bhargava P, Meyerhardt JA, Horgan K, Fuchs CS, Ryan DP. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer. 2007 Aug 1;110(3):581­9.
34. Finberg KE, Sequist LV, Joshi VA, Muzikansky A, Miller JM, Han M, Beheshti J, Chirieac LR, Mark EJ, Iafrate AJ. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn. 2007 Jul;9(3):320­6.
35. Mino­Kenudson M, Hull MJ, Brown I, Muzikansky A, Srivastava A, Glickman J, Park DY, Zuckerberg L, Misdraji J, Odze RD, Lauwers GY. EMR for Barrett's esophagus­related superficial neoplasms PHS 398/2590 (Rev. 5/01)
Page
Biographical Sketch Format Page
Principal Investigator/Program Director (Last, first, middle): offers better diagnostic reproducibility than mucosal biopsy. Gastrointest Endosc. 2007 Oct;66(4):660­6; quiz 767, 769.
36. Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C, Fuchs CS. Capecitabine plus erlotinib in gemcitabine­refractory advanced pancreatic cancer. J Clin Oncol. 2007 Oct 20;25(30):4787­92. 37. Oxnard GR, Fidias P, Muzikansky A, Sequist LV. Non­small cell lung cancer in octogenarians: treatment practices and preferences. J Thorac Oncol. 2007 Nov;2(11):1029­35.
38. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007 Dec 20;450(7173):1235­9.
39. Farris AB, Misdraji J, Srivastava A, Muzikansky A, Deshpande V, Lauwers GY, Mino­Kenudson M. Sessile serrated adenoma: challenging discrimination from other serrated colonic polyps. Am J Surg Pathol. 2008 Jan;32(1):30­5.
40. Tanabe KK, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, Chung RT, Lauwers GY, Kulu Y, Muzikansky A, Kuruppu D, Lanuti M, Goodwin JM, Azoulay D, Fuchs BC. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA. 2008 Jan 2;299(1):53­ 60.
41. Smith EE, Egorova S, Blacker D, Killiany RJ, Muzikansky A, Dickerson BC, Tanzi RE, Albert MS, Greenberg SM, Guttmann CR. Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia. Arch Neurol. 2008 Jan;65(1):94­100.
42. Zhu AX, Holalkere NS, Muzikansky A, Horgan K, Sahani DV. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist. 2008 Feb;13(2):120­5.
43. Belsley NA, Tambouret RH, Misdraji J, Muzikansky A, Russell DK, Wilbur DC. Cytologic features of endocervical glandular lesions: comparison of SurePath, ThinPrep, and conventional smear specimen preparations. Diagn Cytopathol. 2008 Apr;36(4):232­7.
44. Kesari S, Schiff D, Henson JW, Muzikansky A, Gigas DC, Doherty L, Batchelor TT, Longtine JA, Ligon KL, Weaver S, Laforme A, Ramakrishna N, Black PM, Drappatz J, Ciampa A, Folkman J, Kieran M, Wen PY. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol. 2008 Jun;10(3):300­8. Epub 2008 Apr 10.
45. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ. First­line gefitinib in patients with advanced non­small­cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008 May 20;26(15):2442­9. Epub 2008 May 5. Erratum in: J Clin Oncol. 2008 Jul 46. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, Digumarthy S, Muzikansky A, Irimia D, Settleman J, Tompkins RG, Lynch TJ, Toner M, Haber DA. Detection of mutations in EGFR in circulating lung­cancer cells. N Engl J Med. 2008 Jul 24;359(4):366­77.
47. Nardin R, O'Donnell C, Loring SH, Nie R, Hembre K, Walsh J, Arboleda BW, Muzikansky A, Nguyen D, Raynor E. Diaphragm training in amyotrophic lateral sclerosis. J Clin Neuromuscul Dis. 2008 Dec;10(2):56­60.
48. Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, Muzikansky A, Santagata S, Ligon KL, Norden AD, Ciampa A, Bradshaw J, Levy B, Radakovic G, Ramakrishna N, Black PM, Wen PY. Phase II study of protracted daily temozolomide for low­grade gliomas in adults. Clin Cancer Res. 2009 Jan 1;15(1):330­7.
PHS 398/2590 (Rev. 5/01)
Page
Biographical Sketch Format Page
Principal Investigator/Program Director (Last, first, middle): 49. Goulart BH, Clark JW, Lauwers GY, Ryan DP, Grenon N, Muzikansky A, Zhu AX. Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis. J Hematol Oncol. 2009 Mar 16;2:13.
50. Quant EC, Norden AD, Drappatz J, Muzikansky A, Doherty L, Lafrankie D, Ciampa A, Kesari S, Wen PY. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol. 2009 Mar 30. 51. Norden AD, Drappatz J, Muzikansky A, David K, Gerard M, McNamara MB, Phan P, Ross A, Kesari S, Wen PY. J An exploratory survival analysis of anti­angiogenic therapy for recurrent malignant glioma. Neurooncol. 2009 Apr;92(2):149­55. PHS 398/2590 (Rev. 5/01)
Page
Biographical Sketch Format Page
Principal Investigator/Program Director (Last, first, middle): C. Research Support
Ongoing research
(Betensky) 07/01/08 – 6/30/09
HSPH ­ Harvard Center for Neurodegeneration and Repair, Inc. (HCNR)
Translational Neurology Core of the HCNR
Neurologic Clinical Trials Service (NCTS) Biostatistics The goal of this project is to promote research in neurodegenerative diseases with the mission of fostering novel collaborations between scientists at the Harvard Medical School­affiliated labs.
Role: Statistician 2P30 CA06516­42 (Chabner)
05/19/06­11/30/10 NIH­NCI
Cancer Center Support Grant (Biostatistics CORE)
The major goals of this project are to support CORE activities that represent shared resources used by a variety of investigators in different labs throughout the DF/HCC. This is a subcontract through the Dana­Farber Cancer Institute.
Role: Statistician
R01 NS055083­01A1 (Bakshi)
12/01/06 –11/30/10
NIH/NINDS
Gray versus White Matter Brain Atrophy in Multiple Sclerosis
Description: Assess the rate of whole brain gray vs. white matter atrophy in a longitudinal study of patients with MS and age­matched normal controls. Assess the relationship between gray matter atrophy and subsequent neurologic disability.
Role: Statistician
1 P01 CA111519­01A2 (Sykes) 09/12/2006 ­ 07/31/2011 NIH/NCI GVL without GVHD across HLA barriers: Translational Studies
The major goals of this project are to provide the statistical and database support for all research conducted in the Program Project.
Role: Statistician
1 P50 NS051343 01A2 (Furie) 09/20/2006 – 06/30/2011
NIH/NINDS Specialized Program of Translational Research in Acute Stroke (SPOTRIAS)
Role: Statistician Partners' SPOTRIAS will conduct three studies: (1) Safety and efficacy of normobaric hyperoxia on acute stroke, (2) Utility of CTP in predicting tissue outcomes in acute stroke, and (3) a translational study examining markers of oxidative stress, their interaction with matrix metalloproteinases and predictive utility in acute ischemic stroke, which will be performed in animals and humans. Completed Research Support
5R01 NS041409­02 (Greenberg PI ) 1/1/03­12/31/05 NIH/NINDS NC­758 for Prevention of Recurrent Cerebral Hemorrhage
PHS 398/2590 (Rev. 5/01)
Page
Biographical Sketch Format Page
Principal Investigator/Program Director (Last, first, middle): The major goal of this project is to develop a multi­center phase II pilot study of the safety, tolerability and preliminary efficacy of NC­758 for secondary; prevention of recurrent CAA­related intracerebral hemorrhage. Role: Biostatistician
5 U01 CA78284­05 Finkelstein (PI)
07/15/98­12/31/06
NIH­NCI
Coordinating Center for the Cancer Genetics Network
The major goals of this project are to provide statistical support for the Cancer Genetics Network.
Role: Biostatistician
5 P01 AG04953­22 (PI: Blacker) 9/15/2002­7/31/2007
NIH/NIA Age­Related Changes of Cognition in Health and Disease
To study age­related changes of cognition, brain structure and function, and to study ante­mortem markers of very early Alzheimer's disease using neuropsychological testing, MRI, fMRI, SPECT and genetics.
Role: Biostatistician
5 R01 CA68099­08Ahnen (Finkelstein Subcontract)) 9/18/03 – 6/30/08 NIH­NCI
Promoting Colon Cancer Screening in High Risk Populations
Major goals are to provide statistical support for design and analysis of trials.
Role: Biostatistician
PHS 398/2590 (Rev. 5/01)
Page
Biographical Sketch Format Page